Unsustained Response to Benralizumab in Eosinophilic Asthma After 3 Years of Therapy With Mepolizumab

Kurosawa, M; Shimizu, Y; Sutoh, Y; Sutoh, E

Kurosawa, M; Shimizu, Y; Sutoh, Y; Sutoh, E.

Affiliation

Kurosawa, M; Sutoh Hospital. Department of Allergy and Respiratory Medicine. Gunma. Japan
Shimizu, Y; Kaminakai Family Clinic. Division of Respiratory Medicine. Gunma. Japan
Sutoh, Y; Sutoh Hospital. Department of Surgery. Gunma. Japan
Sutoh, E; Sutoh Hospital. Department of Allergy and Respiratory Medicine. Gunma. Japan

J. investig. allergol. clin. immunol ; 31(4): 353-355, 2021. graf

Article in En | IBECS | ID: ibc-215234

Responsible library: ES1.1

Localization: ES15.1 - BNCS

Subject(s)
Key words

Anti-interleukin 5 therapy; Asthma Control Test; Blood eosinophil count; Eosinophilic asthma; FEV1; Terapia anti-interleukina 5; Test de control del asma; Recuento de eosinófilos en sangre; Asma eosinofílica; FEV1

Fulltext

Add to My VHL

XML

Search on Google

Full text: 1 Collection: 06-national / ES Database: IBECS Main subject: Asthma / Eosinophilia / Antibodies, Monoclonal, Humanized Limits: Adult / Female / Humans Language: En Journal: J. investig. allergol. clin. immunol Year: 2021 Document type: Article

Fulltext

Add to My VHL

XML

Search on Google